6-melanoma helper peptide vaccine(University of Virginia)(6-melanoma helper peptide vaccine(University of Virginia))

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名

6MHP

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

黑色素瘤

原研机构

University of Virginia

在研机构-

非在研机构

University of Virginia

最高研发阶段终止临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

6

项与 6-melanoma helper peptide vaccine(University of Virginia) 相关的临床试验

NCT04364230 / Completed临床1/2期IIT

Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma

This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.

开始日期2020-09-28

申办/合作机构

University of Virginia

[+1]

NCT03617328 / Completed临床1/2期IIT

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

This study evaluates whether it is safe to administer a peptide vaccine (6MHP) with adjuvants and the CDX-1127 monoclonal antibody, and whether the adjuvants and the CDX-1127 monoclonal antibody boost immune responses to the vaccine. In this study, the adjuvants are Montanide ISA-51 and polyICLC. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and tissue from a vaccine site.

开始日期2018-11-13

申办/合作机构

University of Virginia

[+1]

NCT02515227 / Completed临床1/2期IIT

A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade

This study evaluates whether it is safe to administer a peptide vaccine in combination with pembrolizumab. This study will also evaluate the effects of the combination of the peptide vaccine and pembrolizumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.

开始日期2016-10-06

申办/合作机构

University of Virginia

[+1]

100 项与 6-melanoma helper peptide vaccine(University of Virginia) 相关的临床结果

登录后查看更多信息

100 项与 6-melanoma helper peptide vaccine(University of Virginia) 相关的转化医学

登录后查看更多信息

100 项与 6-melanoma helper peptide vaccine(University of Virginia) 相关的专利（医药）

登录后查看更多信息

3

项与 6-melanoma helper peptide vaccine(University of Virginia) 相关的文献（医药）

2019-09-01·JAMA Ophthalmology1区 · 医学

Bilateral Mydriasis and Serous Retinal Detachments Associated With Ipilimumab and 6-Melanoma Helper Peptide Vaccine for Cutaneous Melanoma

1区 · 医学

Article

作者: Gaughan, Elizabeth ; Shildkrot, Yevgeniy (Eugene) ; Rodriguez, Christina ; Newman, Steven ; Sieburth, Rebecca

1997-06-01·Journal of Cerebral Blood Flow & Metabolism2区 · 医学

Laminin Peptide Ameliorates Brain Injury by Inhibiting Leukocyte Accumulation in a Rat Model of Transient Focal Cerebral Ischemia

2区 · 医学

Article

作者: Paul J Camarata ; Leo T Furcht ; Walter C Low ; Stephen R Spellman ; Amy P N Skubitz ; Kiyoyuki Yanaka

Postischemic cerebral inflammation has been reported to contribute to ischemic brain damage. During inflammation, constituents of the extracellular matrix such as fibronectin and laminin are recognized by certain integrins or proteoglycans and play an important role in the cell adhesion process. The purpose of this study was to evaluate the efficacy of peptides derived from laminin on leukocyte accumulation, infarct size, and neurological outcome in rats subjected to 1 h of cerebral ischemia and 48 h of reperfusion. Forty-four animals were included in this study: transient ischemia without treatment (Group I), treatment with TG-1 peptide (Group II), GD-1 peptide (Group III), and GD-6 peptide (Group IV). Group II showed a significant reduction of the leukocyte accumulation (p < 0.001) and infarct size (p = 0.015) when compared with Group I. The neurological grade of Group II was also significantly better than in Group I at 48 h after reperfusion (p = 0.012). Based on these data, which are the first to explore the therapeutic potential of this peptide in cerebral ischemia, laminin peptide may offer a novel therapeutic approach to allaying injury in ischemic stroke.

Nature Communications1区 · 综合性期刊

Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

1区 · 综合性期刊

ArticleOA

作者: Ross, Merrick I ; Chianese-Bullock, Kimberly A ; Dengel, Lynn T ; Slingluff, Craig L ; Haas, Naomi B ; Ninmer, Emily K ; Zhu, Hong ; von Mehren, Margaret

AbstractThe critical roles of CD4+ T cells have been understudied for cancer vaccines. Here we report long-term clinical outcomes of a randomized multicenter phase II clinical trial (NCT00118274), where patients with high-risk melanoma received a multipeptide vaccine targeting CD8+ T cells (12MP) and were randomized to receive either of two vaccines for CD4+ (helper) T cells: 6MHP (6 melanoma-specific helper peptides), or tet (a nonspecific helper peptide from tetanus toxoid). Cyclophosphamide (Cy) pre-treatment was also assessed. Primary outcomes for T cell responses to 12MP, 6MHP, and tet were previously reported, suggesting immunogenicity of both vaccines but that CD8 T cell responses to 12MP were lower when tet was replaced with 6MHP. Here, in post-hoc analyses, we report durable prolongation of overall survival by adding 6MHP instead of tet. That benefit was experienced only by male patients. A favorable interaction of 6MHP and Cy is also suggested. Multivariable Cox regression analysis of the intent-to-treat population identify vaccine arm (12MP + 6MHP+Cy) and patient sex (male) as the two significant predictors of enhanced survival. These findings support the value of adding cognate T cell help to cancer vaccines and also suggest a need to assess the impact of patient sex on immune therapy outcomes.

100 项与 6-melanoma helper peptide vaccine(University of Virginia) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黑色素瘤	临床2期	美国	University of Virginia	2015-05-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02515227 (Mel64, CTgov)	临床1/2期	黑色素瘤	22	Pembrolizumab+6MHP (6MHP + Pembrolizumab (PD-1 Antibody-naive Cohort))	範觸積憲製鬱糧憲製獵(鹽壓鬱願窪窪繭夢繭顧) = 蓋鬱網構艱遞鬱積鏇築選襯醖襯憲網顧夢鏇憲 (衊製願選網鏇窪壓鑰製, 蓋糧繭範淵齋繭積選範 ~ 遞廠襯膚獵築範憲選艱) 更多	-	2023-08-25
				Pembrolizumab+6MHP (6MHP + Pembrolizumab (PD-1 Antibody-experienced Cohort))	範觸積憲製鬱糧憲製獵(鹽壓鬱願窪窪繭夢繭顧) = 糧壓醖醖遞憲廠壓廠願選襯醖襯憲網顧夢鏇憲 (衊製願選網鏇窪壓鑰製, 繭齋艱繭鹽醖鹹鹽遞網 ~ 鬱繭糧餘積廠齋蓋襯憲) 更多
NCT02515227 (SITC2021) 人工标引	临床1/2期	黑色素瘤	22	Pembrolizumab+6 melanoma-associated peptides to stimulate helper T cells	(遞糧築廠餘範築襯製積) = injection site reactions, fatigue, anemia, nausea, fever, bruising, and rash 糧願廠鹽廠夢築齋積範 (醖蓋遞鏇遞鬱醖淵製觸 ) 更多	积极	2021-11-11
NCT02425306 (Mel63; CHAMP \| Mel63, CTgov)	临床1/2期	黑色素瘤	48	Montanide ISA-51+6MHP (Arm A:6MHP + Montanide ISA-51)	鹹積獵鬱觸鏇餘憲廠繭(窪膚選繭構簾淵蓋蓋蓋) = 醖築積鏇鹽壓構鑰襯鹽襯觸構淵淵廠鹽選淵齋 (夢齋築遞鏇遞窪觸衊餘, 糧願簾艱積製鑰構簾鏇 ~ 選網簾襯範蓋觸鹽醖鏇) 更多	-	2021-04-29
				Montanide ISA-51+CYCLOPHOSPHAMIDE+6MHP (Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide)	鹹積獵鬱觸鏇餘憲廠繭(窪膚選繭構簾淵蓋蓋蓋) = 壓窪鑰蓋膚齋餘壓獵願襯觸構淵淵廠鹽選淵齋 (夢齋築遞鏇遞窪觸衊餘, 構糧鏇艱簾夢鹹壓簾醖 ~ 選網鏇窪醖網鑰鑰範鹽) 更多
NCT02425306 (Mel63, SITC2019)	临床1/2期	黑色素瘤 Class II MHC	-	6MHPcyclophosphamide (6MHP + IFA)	壓鑰顧觸顧淵願獵襯顧(膚憲鹹艱範獵鬱網夢壓) = 顧鑰構鹽選鹽顧選淵鹽範襯獵醖齋壓艱獵製糧 (觸艱獵願壓遞醖繭膚襯, 11 ~ 26)	积极	2019-11-01
				6MHPcyclophosphamidepolyICLC (6MHP + IFA + polyICLC)	憲齋夢製壓壓窪襯鏇遞(鹹窪願鹽範齋蓋築襯鏇) = 願艱膚膚構膚壓齋鏇獵選簾衊壓獵觸繭醖獵淵 (夢製憲製積製衊獵鬱憲 )
NCT02385669 (Mel62; 6PAC \| Mel62, CTgov)	临床1/2期	黑色素瘤	3	ipilimumab+6MHP	遞簾襯鏇選衊餘壓衊餘(餘獵遞鹹淵選膚築鹹鹽) = 鹹廠淵觸窪獵選鏇夢鏇顧廠艱膚鬱淵鹽顧積衊 (鹽鹽齋鏇夢繭顧艱築艱, 獵構憲壓憲衊遞淵膚繭 ~ 衊淵範壓築廠窪觸顧壓) 更多	-	2019-06-26